Home › Research › Topics › p-tau217
p-tau217
701 studies tagged p-tau217, dated 1989-01-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival 2026-11-01
- Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study 2026-11-01
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease 2026-10-30
Studies
701 studies carry this tag.
Date range
1989 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 123
- Journal of Alzheimer's disease : JAD 53
- Alzheimer's & dementia (Amsterdam, Netherlands) 46
- Alzheimer's research & therapy 36
- medRxiv 29
196 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Test-retest reliability measures are essential for interpretation of meaningful effects over time for plasma and digital outcomes.
-
Phosphorylated-tau (p-tau217) is a promising blood-based biomarker for Alzheimer's dementia (AD) in clinical settings.
-
We analysed 461 participants from the DABNI and SPIN cohorts.
-
We validated results in CSF from 397 participants in the Accelerated Medicine Partnership-Alzheimer’s Disease cohort.
-
Most plasma proteomic studies in Alzheimer’s disease (AD) compare cases and controls cross-sectionally, leaving unresolved which AD-associated proteins mark diagnostic states and which are linked to disease progression.
-
Lower baseline amyloid beta (Aβ)42/40 ratio and higher phosphorylated tau 181 (p-tau181), glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were associated with an increased risk of MCI and dementia; GFAP was most strongly associated.
-
Detection of Alzheimer's disease (AD) before the development of clinical symptoms is critical for enabling the use of new treatments.
-
Two components were identified. Proinflammatory Component 2 was elevated in AD/MCI and in Black/African American participants, and strongly associated with poorer cognition (independently of neurofilament light [NfL], phosphorylated tau 217 [p-tau217], and glial fibrillary acidic protein [GFAP]).
-
Amyloid status was determined by CSF in 347 patients (189 positive [54.5%]) and by PET imaging in 152 patients (66 positive [43.4%]).
-
Of 504 enrolled patients, 491 completed POD assessment (mean [SD] age, 68.4 [8.3] years; 385 [78.4%] male), of whom 106 (21.6%) developed POD.
-
Participants with Elevated/High %p-tau217 exhibited accelerated cognitive decline, hippocampal atrophy, and significantly higher risks of progression to MCI (hazard ratio [HR] > 6.0) and dementia (HR > 9.9).
-
The levels of four CSF biomarkers correlated to EOAD signature atrophy.
-
The NPTX2/p-tau ratio enhanced diagnostic performance of standalone NPTX2 and p-tau, particularly for DLB and FTLDrs (area under the curve [AUC]NPTX2/p-tau = 0.78-0.79 vs. AUCNPTX2 = 0.63-0.70 and AUCp-tau = 0.59-0.75), and was more strongly associated with cognition.
-
Dementia with Lewy bodies (DLB), a synucleinopathy, is the second most common form of dementia after Alzheimer's disease (AD).
-
A total of 18 high-quality studies comprising 24 independent datasets and 4,736 participants were included.
-
Higher plasma p-tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p-tau217 in cognitively impaired individuals (β = -0.49, p < 0.001).
-
Plasma phosphorylated tau217 has been suggested as a core biomarker for establishing a biological Alzheimer's disease diagnosis.
-
16/100
Blood-based biomarkers have expanded access to biologically supported diagnosis of Alzheimer's disease (AD), particularly through measurement of amyloid-beta (Aβ) and phosphorylated tau species1-3.
-
Our findings confirm the diagnostic value of urinary β-amyloid protein detection in MCI and AD-related dementia.
-
Compared with healthy controls, patients with ALS - particularly those with cognitive impairment (ALSci) or ALS-FTD - showed elevated AD-related biomarkers.
-
In participants who progressed to amyloid-positive MCI, plasma p-tau181/Aβ42 and GFAP diverged from stable controls earliest (about 13 and 12 years before symptom onset, respectively), followed by Aβ42/Aβ40, p-tau181, and NfL, all of which became abnormal before symptom onset.
-
Multiple proteinopathies commonly coexist in neurodegenerative diseases, making it essential to evaluate plasma biomarker performance in these complex diseases.
-
To improve clinical utility, a dual threshold approach was applied to maximize predictive values and positive likelihood ratios while minimizing the proportion of indeterminate results.
-
The assay demonstrated strong analytical performance, with repeatability and intermediate precision (%CV < 7%) and an LLoQ of 0.12 pg/mL.
-
16/100
The clock claims are unsupported.
-
Neuropathology cases included 46 Parkinson's disease and 10 dementia with Lewy bodies, and clinical cases included 173 Parkinson's disease, and 64 controls.
-
A total of 917 participants had a mean baseline age of 67.4 years (SD 12.1), 49.4% were female, and 48.6% self-identified as Black.
-
Plasma p-tau217 was 57% higher in subjects with at least one APOE ε4 allele, increased with age, was higher in males, and negatively correlated with brain volume measures by magnetic resonance imaging.
-
While the biomarkers available for Alzheimer's disease are continually expanding, including clinically approved blood tests, not all of the relationships between various biomarkers have been fully elucidated.
-
Phosphorylated-tau 217 (pTau217) is currently the most promising blood-based biomarker for accurately detecting Alzheimer's disease (AD) pathology.
-
MES-defined cognitive impairment (≤-2 standard deviation [SD] deviation after adjustment for demographics) was identified in 12.4% of participants.
-
Specific plasma biomarker combinations predicted amyloid burden in the precuneus, tau in the entorhinal cortex, hippocampal atrophy, and memory decline.
-
Among 163 patients (mean age 69.3 ± 7.4 years, 52% female), plasma p-tau217 distinguished A+ from A- individuals (area under the curve [AUC] 0.90, 81% sensitivity, 91% specificity).
-
Carriers had lower LAS-FNAME performance (P < 0.001) and higher p-tau217 (P < 0.001), NfL (P = 0.013), and GFAP (P < 0.001) levels than non-carriers.
-
a Structured abstract BACKGROUND Over the past couple of decades, the role of infections, as well as the involvement of the immune system, have been highlighted in the development of dementia.
-
Plasma p-tau217 demonstrated the strongest discrimination of Core1 positivity (area under the curve [AUC] = 0.95) and showed the steepest increase with disease progression.
-
Alzheimer's disease (AD) presents a critical global challenge, accounting for over 60 % of the 57 million current dementia cases worldwide, with prevalence projected to exceed 100 million by 2050.
-
Plasma p-tau217 levels measured using Lumipulse and Simoa assays were highly correlated (p < 0.001).
-
The clinical utility of plasma phosphorylated tau at threonine 217 (p-tau217) levels as a diagnostic tool for cognitive disorders in real-world settings remains uncertain.
-
Plasma phosphorylated tau (p-tau) biomarkers offer a minimally invasive alternative for detecting Alzheimer’s disease (AD) pathology.
-
54/100
AD-MCI and AD-DEM patients showed increased p-tau217 and spectral slowing (higher theta, lower alpha).
-
Among the individual plasma p-tau variants, p-tau217 consistently outperformed p-tau181 and p-tau231.
-
Age acceleration was significantly associated with sex, clinical diagnosis, and levels of eight plasma biomarkers, including P-tau217 levels.
-
52/100
Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer's disease (AD).
-
The annual number of health insurance claims for p-tau181 testing gradually increased from 1358 (2014) to 3420 (2023); 79-86% of claims were from inpatient settings throughout the study period.
-
The observed phenotypic and genetic associations highlight shared underlying mechanisms among plasma biomarkers.
-
Elevated CSF p-Tau181 and NfL levels were associated with greater decline in memory and executive function.
-
57/100
Lactate metabolic clearance rate did not differ between CH and CI subjects (p = 0.988).
-
Cognition ranged from high to early cognitive decline (median Mini-Mental State Examination [MMSE] score = 26).
-
Plasma biomarkers have emerged as promising less invasive alternatives for Alzheimer's disease (AD) detection.
From across this tag
8 of the 699 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Symptom-Guided Blood Biomarker Testing for Alzheimer's Disease
- Alzheimer’s disease blood-based biomarkers in the Boston Latino Aging Study (BLAST): Associations with cognition and depressive symptoms
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease
- Plasma Neurofilament Light Chains as Blood-Based Biomarkers for Early Diagnosis of Canine Cognitive Dysfunction Syndrome
- A genome-wide association study of longitudinal change in CSF tau among non-demented elderly
- Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo
- Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels
- Plasma eMTBR-tau as a marker of clinical stage and progression across the Alzheimer’s disease continuum